← All trials
NCT06648304
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Apr 25, 2023
- Primary completion
- Jun 17, 2024
- Completion date
- Jun 17, 2024
- First posted
- Oct 18, 2024
- Last posted
- Oct 18, 2024
- Enrollment
- 614
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Auzone Biological Technology Pty LtdLead sponsor
- People's Liberation Army of ChinaOfficial
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.